Skip to main content
    P

    Procept Biorobotics Corp (PRCT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $23.54
    -0.26 (-1.09%)

    Market Cap: $1.37B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Procept Biorobotics Corp (PRCT) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Procept Biorobotics (PRCT) to earn -$1.72 per share in the fiscal year ending Dec 31, 2026, on revenue of $395.29M. Of 15 analysts, 5 rate the stock Buy or Strong Buy, 9 Hold and 1 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$1.23.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 2.67, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 33% of the ratings.

    RatingAnalystsShare
    Strong Buy213.3%
    Buy320.0%
    Hold960.0%
    Sell00.0%
    Strong Sell16.7%
    Consensus
    Hold
    Total analysts
    15

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 19.8%.

    Fiscal year ending Dec 31, 2026
    -$1.72
    EPS consensus, revenue $395.29M
    Fiscal year ending Dec 31, 2027
    -$1.23
    EPS consensus, revenue $473.67M
    Next report
    Feb 23, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.72-$1.80 to -$1.6313$395.29M$389.00M to $401.51M14
    Dec 31, 2027-$1.23-$1.58 to -$0.8613$473.67M$458.33M to $483.04M14

    Quarterly Estimates

    The EPS consensus falls from -$0.25 for the quarter ending Dec 31, 2026 to -$0.43 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.25-$0.27 to -$0.2017$120.40M$102.76M to $131.88M16
    Mar 31, 2027-$0.43-$0.52 to -$0.3411$104.60M$101.40M to $108.20M10

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 3 upward and 8 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202722
    Quarter ending Mar 31, 202716

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.68.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$1.72-$1.68-$1.68-$1.68-$1.68N/A
    Fiscal year ending Dec 31, 2027-$1.23-$1.17-$1.15-$1.15-$1.15N/A
    Quarter ending Mar 31, 2027-$0.43-$0.38-$0.38-$0.38-$0.38N/A

    Frequently Asked Questions About PRCT

    What is the PRCT stock forecast?

    Consensus analyst estimates put Procept Biorobotics's EPS at -$1.72 for the fiscal year ending Dec 31, 2026, on revenue of $395.29M. The consensus rating from 15 analysts is Hold.

    How do analysts rate PRCT stock?

    Of 15 analysts covering Procept Biorobotics, 2 rate it Strong Buy, 3 Buy, 9 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from PRCT next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.72, with estimates from -$1.80 to -$1.63 from 13 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.23, with estimates from -$1.58 to -$0.86 from 13 analysts.

    What revenue do analysts expect from Procept Biorobotics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $395.29M, with estimates from $389.00M to $401.51M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $473.67M, with estimates from $458.33M to $483.04M.

    How many analysts cover PRCT?

    15 analysts rate Procept Biorobotics stock, and 13 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.